Advancements in predictive in silico models for ADME

Current Chemical Biology

Volumn 2, Issue 3, 2008, Pages 215-228

  Chohan, Kamaldeep K ^a   Paine, Stuart W ^a   Waters, Nigel J ^a,b  

^a ASTRAZENECA   (United Kingdom)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

ADME; Drug metabolism; In silico; Pharmacokinetics; Protein transporters; QSAR; Statistical methods

Indexed keywords

EID: 54749091722     PISSN: 18723136     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231308785739747     Document Type: Review

References (109)

1. Hodgson J. ADMET - turning chemicals into drugs. Nat Biotechnol 2001; 19(8): 722-726.
2. Roberts SA. High-throughput screening approaches for investigating drug metabolism and pharmacokinetics. Xenobiotica 2001; 31: 557-89.
3. Yu H. Adedoyin A. ADME-Tox in drug discovery: Integration of experimental and computational technologies. Drug Discov Today 2003; 8: 852-861.
4. Van de Waterbeemd H, Gifford E. ADMET in silico modelling: Towards prediction paradise? Nat Rev Drug Discov 2003; 2: 192-204.
5. Winkler DA. The role of QSAR in biomolecular discovery. Brief Bioinfo 2002; 3: 73.
6. Ekins S, Waller CL, Swaan PW, Cruciani G, Wrighton SA, Wikel JH. Progress in predicting human ADME parameters in silico. J Pharm Tox Meth 2000; 44: 251-272.
7. Akamatsu M. Current state and perspectives of 3D-QSAR. Curr Top Med Chem 2002; 2: 1381-1394.
8. Penzotti JE, Landrum GA, Putta S. Building predictive ADMET models for early decisions in drug discovery. Drug Discov Dev 2004; 7: 49-61.
9. Testa B, Vistoli G, Pedretti A. Musings of ADME Predictions and structure-activity relations. Chem Biodivers 2005; 2: 1411-1427.
10. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997; 23: 3-25.
11. Clark DE. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. J Pharm Sci 1999; 88: 807-814.
12. Artursson P, Karlsson J. Correlation between oral drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991; 175: 880-885.
13. Van de Waterbeemd H, Camenisch G, Folkers G, Raevsky OA. Estimation of Caco-2 cell permeability using calculated molecular descriptors. Quant Struct-Act Relat 1996; 15: 480-490.
14. Ren S, Lien EJ. Caco-2 cell permeability vs human gastrointestinal absorption: QSPR analysis. Prog Drug Res Fortschritte der Arzneimittelforschung Progres des recherches pharmaceutics 2000; 54: 1-23.
15. Yamashita F, Wanchana S, Hashida M. Quantitative structure/property relationship analysis of Caco-2 permeability using a genetic algorithm-based partial least squares method. J Pharm Sci 2002; 91: 2230-2239.
16. Palm K, Stenberg P, Luthman K, Artursson P. Polar molecular surface properties predict and the intestinal absorption of drugs in humans. Pharm Res 1997; 14: 568-571.
17. Palm K, Luthman K, Ungell AL, Strandlund G, Artursson P. Correlation of drug absorption with molecular surface properties. J Pharm Sci 1996; 85: 32-39.
18. Sugawara M, Takekuma Y, Yamada H, Kobayashi M, Iseki K, Miyazaki K. A general approach for the prediction of intestinal absorption of drugs: Regression analysis using the physiochemical properties and drug-membrane electrostatic interaction. J Pharm Sci 1998; 87: 960-966.
19. Oprea TI, Gottfries J. Toward minimalistic modelling of oral drug absorption. J Mol Graph Mod 1999; 94: 261-274.
20. Agatonovic-Kustrin S, Beresford R, Yusof APM. Theoretically-derived molecular descriptors important in human intestinal absorption. J Pharm Biomed Anal 2001; 25: 227-237.
21. Zhao YH, Le J, Abraham MH, et al. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. J Pharm Sci 2001; 90: 749-784.
22. Zhao YH, Abraham MH, Le J, et al. Rate-limited steps of human oral absorption and QSAR studies. Pharm Res 2002; 19: 1446-1457.
23. Raevsky OA, Schaper KJ, Artursson P, McFarland JW. A novel approach for prediction of intestinal absorption of drugs in humans based on hydrogen bond descriptors and structural similarity. Struct-Act Relat 2002; 20: 402-413.
24. Deretey E, Feher M, Schmidt JM. Rapid prediction of human intestinal absorption. Quant Struct-Act Relat. 2002; 21: 493-506.
25. Klopman G, Stefan LR, Saiakhov RD. ADME evaluation 2. A computer model for the prediction of intestinal absorption in humans. Eur J Pharm Sci 2002; 17: 253-263.
26. Zmuidinavicius D, Didziapetris R, Japertas P, Avdeef A, Petrauskas A. Classification structure-activity relations (C-SAR) in prediction of human intestinal absorption. J Pharm Sci 2003; 92: 621-633.
27. Perez MAC, Sanz MB, Torres LR, Avalos RG, Gonzalez MP, Diaz HG. A topological sub-structural approach for predicting human intestinal absorption of drugs. Eur J Med Chem 2004; 39: 905-916.
28. Deconinck E, Hancock T, Coomans D, Massart DL, Vander Heyden Y. Classification of drugs in absorption classes using the classification and regression trees (CART) methodology. J Pharm Biol Anal 2005; 39: 91-103.
29. Jones R, Connolly PC, Klamt A, Diedenhofen M. Use of surface charges from DFT calculations to predict intestinal absorption. J Chem Inf Model 2005; 45: 1337-1342.
30. Polley MJ, Burden FR, Winkler DA. Predictive human intestinal absorption QSAR models using Bayesian regularized neural networks. Aust J Chem 2005; 58: 859-863.
31. Subramanian G, Kitchen DB. Computational approaches for modelling human intestinal absorption and permeability. J Mol Model 2006; 12: 577-589.
32. Lombardo F, Gifford E, Shalaeva MY. In silico ADME prediction: Data, models, facts and myths. Mini Rev Med Chem 2003; 3: 861-875.
33. Kratochwil NA, Huber W, Muller F, Kansy M, Gerber PR. Predicting plasma protein binding of drugs - revisited. Curr Opin Drug Discov Dev 2004; 7: 507-512.
34. Yap CW, Chen YZ. Quantitative structure-pharmacokinetic relationships for drug distribution properties by using general regression neural network. J Pharm Sci 2005; 94: 153-168.
35. Ecker GF, Noe CR. In silico prediction models for blood-brain barrier permeation. Curr Med Chem 2004; 11: 1617-1628.
36. Ghuman J, Zunszain PA, Petitpas I, Bhattacharya AA, Otagiri M, Curry S. Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol 2005; 353: 38-52.
37. Lombardo F, Obach RS, Shalaeva MY, Gao F. Prediction of human volume of distribution values for neutral and basic drugs. 2: Extended data set and leave-class-out statistics. J Med Chem 2004; 47: 1242-1250.
38. Turner JV, Maddalena DJ, Cutler DJ. Pharmacokinetic parameter prediction from drug structure using artificial neural networks. Int J Pharm 2004; 270: 209-219.
39. Gleeson MP, Waters NJ, Paine SW, Davis AM. In silico human and rat Vss quantitative structure - activity relationship models. J Med Chem 2006; 49: 1953-1963.
40. Lombardo F, Obach RS, DiCapua FM, et al. A hybrid mixture discriminant analysis-random forest computational model for the prediction of volume of distribution of drugs in human. J Med Chem 2006; 49: 2262-2267.
41. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992; 22: 1-21.
42. Miners JO, Mackenzie PI. Drug glucuronidation in humans. Pharmacol Ther 1991; 51: 347-369.
43. Lewis DFV. Quantitative structure-activity relationships (QSARs) within the cytochrome P450 system: QSARs describing substrate binding, inhibition and induction of P450s. Inflammopharmacology 2003; 11(1): 43-73.
44. Long A, Walker JD. Quantitative structure-activity relationships for predicting metabolism and modelling cytochrome P450 enzyme activities. Environ Toxicol Chem 2003; 22(8): 1894-1899.
45. Smith PA, Sorich MJ, Low LSC, McKinnon RA, Miners JO. Towards integrated ADME prediction: past, present and future directions for modelling metabolism by UDP-glucuronosyltransferases. J Mol Graph Mod 2004; 22: 507-517.
46. Ekins S, Bravi G, Wikel JH, Wrighton SA. Three-Dimensional Quantitative Structure Activity Relationship (3D-QSAR) Analysis of CYP 3A4 Substrates. J Pharmacol Exp Ther 1999; 291: 424-433.
47. Ekins S, Bravi G, Binkley S, et al. Three- and Four-Dimensional Quantitative Structure Activity Relationship Analyses of Cytochrome P-450 3A4 Inhibitors. J Pharmacol Exp Ther 1999; 290: 429-438.
48. Wanchana S, Yamashita F, Hashida M. QSAR Analysis of the Inhibition of Recombinant CYP 3A4 Activity by Structurally Diverse Compounds Using a Genetic Algorithm-Combined Partial Least Squares Method. Pharm Res 2003; 20: 1401-1408.
49. Molnar L, Keseru GM. A Neural Network Based Virtual Screening of Cytochrome P450 3A4 Inhibitors. Bioorg Med Chem Lett 2002; 12: 419-421.
50. de Groot MJ, Ackland MJ, Horne VA, Alex AA, Jones BC. Novel Approach to Predicting P450 Mediated Drug Metabolism. The Development of a Combined Protein and Pharmacophore Model for CYP2D6. J Med Chem 1999; 42: 1515-1524.
51. Haji-Momenian S, Rieger JM, Macdonald TL, Brown ML. Comparative Molecular Field Analysis and QSAR on Substrates Binding to Cytochrome P450 2D6. Bioorg Med Chem 2003; 11: 5545-5554.
52. Ekins S, Berbaum J, Harrison RK. Generation and Validation of Rapid Computational Filters for CYP2D6 and CYP3A4. Drug Metab Dispos 2003; 31: 1077-1080.
53. Kemp CA, Flanagan JU, van Eldik AJ, et al. Validation of Model of Cytochrome P450 2D6: An in silico Tool for Predicting Metabolism and Inhibition. J Med Chem 2004; 47: 5340-5346.
54. Susnow RG, Dixon SL. Use of Robust Classification Techniques for the Prediction of Human Cytochrome P450 2D6 Inhibition. J Chem Inf Comput Sci 2003; 43: 1308-1315.
55. O'Brien SE, de Groot MJ. Greater Than the Sum of Its Parts: Combining Models for Useful ADMET Prediction. J Med Chem 2005; 48: 1287-1291.
56. Brosen K. Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Clin Pharmacokinet 1995; 29: 20-25.
57. Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 1991; 4: 391-407.
58. Jeppesen U, Loft S, Poulsen HE, Broesen KA. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996; 6: 213-222.
59. So FV, Guthrie N, Chambers AF, Moussa M, Carroll KK. Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutr Cancer 1996; 26: 167-181.
60. Wattenberg LW. Inhibition of carcinogenesis by minor dietary constituents. Cancer Res 1992; 52: 2085-2091.
61. Steinmetz KA, Potter JD. Vegetables, fruit, and cancer. II. Mechanisms. Cancer Causes Control 1991; 2: 427-442.
62. Lewis FV, Modi S, Dickins M. Quantitative Structure-Activity Relationships (QSARs) Within Substrates of Human Cytochrome P450 Involved in Drug Metabolism. Drug Metab Drug Interact 2001; 18: 221-242.
63. Moon T, Chi MH, Kim DH, Yoon CN, Choi YS. Quantitative Structure-Activity Relationships (QSAR) Study of Flavonoid Derivatives for Inhibition of Cytochrome P450 1A2. Quant Struct-Act Relat 2000; 19: 257-263.
64. Iori F, da Fonseca R, João Ramos M, Menziani MC. Theoretical quantitative structure-activity relationships of flavone ligands interacting with cytochrome P450 1A1 and 1A2 isozymes. Bioorg Med Chem 2005; 13: 4366-4374.
65. Chohan KK, Paine SW, Mistry J, Barton P, Davis AM. A Rapid Computational Filter for Cytochrome P450 1A2 Inhibition Potential of Compound Libraries. J Med Chem 2005; 48: 5154-5161.
66. Korhonen LE, Minna R, Mähönen NJ, Wittekindt C, Poso A. Predictive Three-Dimensional Quantitative Structure-Activity Relationship of Cytochrome P450 1A2 Inhibitors. J Med Chem 2005; 48: 3808-3815.
67. Rendic S, di Carlo F. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997; 29: 413-580.
68. Miners J, Birkett D. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525-538.
69. Langowski J, Long A. Computer systems for the prediction of xenobiotic metabolism. Adv Drug Deliv Rev 2002; 54: 407-415.
70. Mancy A, Dijols S, Poli S, Guengerich P, Mansuy D. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP2C9 and consequences for the substrate binding site topology of CYP 2C9. Biochemistry 1996; 35: 16205-16212.
71. Takahashi H, Sato T, Shimoyama Y, et al. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. Clin Pharmacol Ther 1999; 66: 569-581.
72. Locuson CW, Wahlstrom JL, Rock DA, Jones JP. A new class of CYP2C9 inhibitors: probing 2C9 specificity with high-affinity benzbromarone derivatives. Drug Metab Dispos 2003; 31: 967-971.
73. Lewis DFV, Dickins M, Weaver RJ, Eddershaw PJ, Goldfarb PS, Tarbit MH. Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization in the CYP2C subfamily. Xenobiotica 1998; 28: 235-268.
74. Afzelius L, Masimirembwa CM, Karlen A, Andersson TB, Zamora I. Discriminant and qualitative PLS analysis of competitive CYP2C9 inhibitors versus non-inhibitors using alignment independent GRIND descriptors. J Comput-Aided Mol Des 2002; 16: 443-458.
75. Afzelius L, Zamora I, Masimirembwa CM, et al. Conformer- and Alignment-Independent Model for Predicting Structurally Diverse Competitive CYP2C9 Inhibitors. J Med Chem 2004; 47: 907-914.
76. Locuson CW, Rock DA, Jones JP. Quantitative Binding Models for CYP2C9 Based on Benzbromarone Analogues. Biochemistry 2004; 43: 6948-6958.
77. Yap CW, Chen YZ. Prediction of Cytochrome P450 3A4, 2D6, and 2C9 Inhibitors and Substrates by Using Support Vector Machines. J Chem Inf Model 2005; 45: 982-992.
78. Locuson CW, Suzuki H, Rettie AE, Jones JP. Charge and Substituent Effects on Affinity and Metabolism of Benzbromarone-Based CYP2C19 Inhibitors. J Med Chem 2004; 47: 6768-6776.
79. Cruciani G, Carosati E, De Boeck B, et al. MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist. J Med Chem 2005; 48: 6970-6979.
80. Testa B, Balmat A-L, Long A, Judson P. Predicting drug metabolism - An evaluation of the expert system METEOR. Chem Biodivers 2005; 2: 872-885.
81. Embrechts MJ, Ekins S. Classification of metabolites with kernel partial least squares (K-PLS). Drug Metab Dispos 2007; in press.
82. MacKenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Belanger A. The UDP-glycosyltransferase gene superfamily-recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997; 7: 255-269.
83. Ritter JK, Crawford JM, Owens IS. Cloning of two human liver bilirubin UDP-glucuronosyl-transferase cDNAs with expression in COS-1 cells. J Biol Chem 1991; 266: 1043-1047.
84. Ebner T, Remmel RP, Burchell B. Human bilirubin UDP-glucuronosyltransferase catalyses the glucuronidation of ethinylestradiol. Mol Pharmacol 1993; 43: 649-654.
85. Senafi SB, Clarke DJ, Burchell B. Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem J 1994; 303: 233-240.
86. Sorich MJ, Smith PA, McKinnon RA, Miners JO. Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates. Pharmacogenetics 2002; 12: 635-645.
87. Green MD, Telphy TR. Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalysed by expressed human UGT1.4 protein. Drug Metab Dispos 1996; 24: 356-363.
88. Green MD, Bishop WP, Telphy TR. Expressed Human UGT1.4 Protein Catalyses the Formation of Quaternary Ammonium-Linked Glucuronides. Drug Metab Dispos 1995; 23: 299-302.
89. Smith PA, Sorich MJ, McKinnon RA, Miners JO. Pharmacophore and quantitative structure activity relationship (QSAR) modelling: complementary approaches to the rationalisation and prediction of UDP-glucuronosyltransferase 1A4 (UGT1A4) substrate selectivity. J Med Chem 2002; 46: 1617-1626.
90. Ethel BT, Ekins S, Wang JB, Burchell B. Quantitative structure activity relationships for the glucuronidation of simple phenols by expressed human UGT1A6 and UGT1A9. Drug Metab Dispos 2002; 30: 734-738.
91. Sorich MJ, McKinnon RA, Miners JO, Smith PA. Comparison of linear and non-linear classification algorithms for the prediction of chemical metabolism by UDP-glucuronosyltransferase isoforms. J Chem Inform Comp Sci 2003; 43: 2019-2024.
92. Sorich MJ, McKinnon RA, Miners JO, Winkler DA, Smith PA. Rapid Prediction of Chemical Metabolism by Human UDP-glucuronosyltransferase Isoforms Using Quantum Chemical Descriptors Derived with the Electronegativity Equalisation Method. J Med Chem 2004; 47: 5311-5317.
93. Ghibellini G, Leslie EM, Brouwer KLR. Methods to evaluate biliary excretion of drugs in humans: An updated review. Mol Pharmaceut 2006; 3: 198-211.
94. Williams JA, Hyland R, Jones BC, et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: A pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 2004; 32: 1201-1208.
95. Smith DA, van de Waterbeemd H, Walker DK, Mannhold R, Kubinyi H, Timmerman H. Pharmacokinetics and metabolism in drug design (Methods & principles in medicinal chemistry). John Wiley, New York, 2000.
96. Doddareddy MR, Cho YS, Koh HY, Kim DH, Pae AN. In silico renal clearance model using classical Volsurf approach. J Chem Inf Model 2006; 46: 1312-1320.
97. Proost JH, Roggeveld J, Wierda JMKH, Meijer DKF. Relationship between chemical structure and physicochemical properties of series of bulky organic cations and their hepatic uptake and biliary excretion rates. J Pharmacol Exp Ther 1997; 282: 715-726.
98. Hirom PC, Millburn P, Smith RL, Williams RT. Species variations in the threshold molecular-weight factor for the biliary excretion of organic anions. Biochem J 1972; 129: 1071-1077.
99. Hirom PC, Millburn P, Smith RL. Bile and urine as complementary pathways for the excretion of foreign organic compounds. Xenobiotica 1976; 6: 55-64.
100. Liu X, Chism JP, LeCluyse EL, Brouwer KR, Brouwer KL. Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab Dispos 1999; 27: 637-644.
101. Bi Y, Kazolias D, Duignan DB. Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab Dispos 2006; 34: 1658-1665.
102. Crivori P, Reinach B, Pezzetta D, Poggesi I. Computational models for identifying potential P-glycoprotein substrates and inhibitors. Mol Pharmaceut 2006; 3: 33-44.
103. Hirano H, Kurata A, Onishi Y, et al. High-speed screening and QSAR analysis of human ATP-binding cassette transporter ABCB11 (Bile salt export pump) to predict drug-induced intrahepatic cholestasis. Mol Pharmaceut 2006; 3: 252-265.
104. Murakami S, Nakashima R, Yamashita E, Matsumoto T, Yamaguchi A. Crystal structures of a multidrug transporter reveal a functionally rotating mechanism. Nature 2006; 443: 173-179.
105. Meredith D, Price RA. Molecular modeling of PepT1 - Towards a structure. J Membr Biol 2006; 213: 79-88.
106. Zhang X, Shirahatti NV, Mahadevan D, Wright SH. A conserved glutamate residue in transmembrane helix 10 influences substrate specificity of rabbit OCT2 (SLC22A2). J Biol Chem 2005; 280: 34813-34822.
107. Perry JL, Dembla-Rajpal N, Hall LA, Pritchard JB. A Three-dimensional model of human organic anion transporter 1. J Biol Chem 2006; 281: 38071-38079.
108. Hu YN, Walker S. Remarkable structural similarities between diverse glycosyltransferases. Chem Biol 2002; 9: 1287-1296.
109. Van der Aar EM, Bouwman T, Commandeur JNM, Vermeulen NPE. Structure-activity relationships for chemical and glutathione S-transferase-catalysed glutathione conjugation reactions of a series of 2-substituted 1-chloro-4-nitrobenzenes. J Biochem 1996; 320: 531-540.